On September 21 @ 8am PST / 11am EDT, the Canadian Treatment Action Council (CTAC) will be hosting a webinar about the upcoming hep C treatment AbbVie 2D – GT4 (ombitasvir / paritaprevir / ritonavir). The treatment is about to undergo a CADTH Common Drug Review (CDR), which is now collecting patient input.
The patient input survey that will follow CTAC’s webinar is different from PHCN’s patient input survey or PHCN’s loved ones / caregivers survey. Please consider filling out the PHCN survey that was created for you as well as CTAC’s survey.
Registration for the CTAC webinar is required. Click here to register or for more information about the webinar.
About the Canadian Treatment Action Council (CTAC)
CTAC is a Canadian non-governmental organization led by and for people living with HIV and HIV/HCV co-infection. Since 1996, they have been working to secure and ensure equitable, affordable, and timely access to treatment and care and support for people in Canada living with HIV and HIV/HCV co-infection.